Publication Alert: Pharmacokinetics and Dosimetry of Lutetium-177 Zadavotide Guraxetan

New data from the Phase 3 ECLIPSE clinical trial of investigational lutetium-177 (Lu-177) zadavotide guraxetan in patients with metastatic castration-resistant prostate cancer (mCRPC) have been presented at the ASCO Genitourinary Cancers Symposium 2026.

The publication presents the first pharmacokinetics (PK) and dosimetry data from a nonrandomized substudy of 26 patients. The analysis evaluated the biodistribution and radiation absorbed doses of Lu-177 zadavotide guraxetan in organs of interest.

The findings demonstrated favorable organ radiation absorbed doses, with projected mean cumulative renal doses remaining low for a six-cycle treatment regimen. These findings supported an amendment to the ECLIPSE trial protocol to allow treatment with 7.4 GBq for up to six cycles.

The data highlight the role of dosimetry in understanding radiation exposure and informing treatment protocols for radioligand therapy.

Publication

Pharmacokinetics and Dosimetry of Lutetium Lu 177 Zadavotide Guraxetan in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC): Results From the ECLIPSE Sub-study

Read the abstract: https://www.asco.org/abstracts-presentations/256437

Lutetium-177 zadavotide guraxetan is investigational and has not been approved by any regulatory authority.